AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment

Reuters12-18 06:00

AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment

AptarGroup Inc. announced that its Bidose (BDS) Liquid Nasal Spray System has been selected as the delivery mechanism for CARDAMYST™ (etripamil) Nasal Spray, which has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults. The approval marks a collaboration between AptarGroup Inc. and Milestone Pharmaceuticals Inc., the developer of CARDAMYST, and highlights Aptar's expanding role in providing innovative drug delivery solutions for new therapeutic areas.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217190273) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592946868?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592946868","market":"fut","top_or_hot":-1,"title":"AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AptarGroup Inc. announced that its Bidose (BDS) Liquid Nasal Spray System has been selected as the delivery mechanism for CARDAMYST™ (etripamil) Nasal Spray, which has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults. The approval marks a collaboration between AptarGroup Inc. and <a href=\"https://laohu8.com/S/MIST\">Milestone Pharmaceuticals Inc.</a>, the developer of CARDAMYST, and highlights <a href=\"https://laohu8.com/S/ATR\">Aptar</a>'s expanding role in providing innovative drug delivery solutions for new therapeutic areas.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217190273) on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 06:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AptarGroup Inc. announced that its Bidose (BDS) Liquid Nasal Spray System has been selected as the delivery mechanism for CARDAMYST™ (etripamil) Nasal Spray, which has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults. The approval marks a collaboration between AptarGroup Inc. and <a href=\"https://laohu8.com/S/MIST\">Milestone Pharmaceuticals Inc.</a>, the developer of CARDAMYST, and highlights <a href=\"https://laohu8.com/S/ATR\">Aptar</a>'s expanding role in providing innovative drug delivery solutions for new therapeutic areas.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217190273) on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL7QDrpY:1","article_id":"2592946868","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592946868","pubTimestamp":1766008827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AptarGroup Inc. announced that its Bidose  Liquid Nasal Spray System has been selected as the delivery mechanism for CARDAMYST  Nasal Spray, which has received approval from the U.S. Food and Drug Administration  for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia  in adults. The approval marks a collaboration between AptarGroup Inc. and Milestone Pharmaceuticals Inc., the developer of CARDAMYST, and highlights Aptar's expanding role in providing innovative drug delivery solutions for new therapeutic areas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire  on December 17, 2025, and is solely responsible","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ATR":"Aptar","MIST":"Milestone Pharmaceuticals Inc.","BK4126":"金属与玻璃容器"},"translate_title":"AptarGroup获得FDA批准用于CARDAMYST治疗的双剂量鼻腔给药系统","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIST":0.9,"ATR":0.9},"content_text":"AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment\n    \n\n        AptarGroup Inc. announced that its Bidose (BDS) Liquid Nasal Spray System has been selected as the delivery mechanism for CARDAMYST™ (etripamil) Nasal Spray, which has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults. The approval marks a collaboration between AptarGroup Inc. and Milestone Pharmaceuticals Inc., the developer of CARDAMYST, and highlights Aptar's expanding role in providing innovative drug delivery solutions for new therapeutic areas.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217190273) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592946868","isCrawlerRequest":true}